Protalix BioTherapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDProtalix BioTherapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 92), indicating clear outperformance against the broad market. Earnings contraction of 11% provides fundamental context to the price action. However, price is extended 24% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.89 | -0.43% | BELOW |
| 50 SMA | $2.31 | +24.46% | ABOVE |
| 100 SMA | $2.19 | +31.51% | ABOVE |
| 150 SMA | $2.04 | +41.12% | ABOVE |
| 200 SMA | $1.91 | +50.56% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PLX in an uptrend right now?
PLX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PLX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PLX overbought or oversold?
PLX's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is PLX outperforming the market?
PLX has a Relative Strength (RS) Rating of 92 out of 99. Yes, PLX is a market leader, outperforming 92% of all stocks over the past 12 months.
Where is PLX in its 52-week range?
PLX is trading at $2.88, which is 90% of its 52-week high ($3.19) and 83% above its 52-week low ($1.32).
How volatile is PLX?
PLX has a Beta of 0.74 and 52-week volatility of 79%. It's less volatile than the S&P 500 - generally more stable.